PLA2G5 and cancer: Also, the regulatory T cells treated with hvPLA2 showed a higher expression of programmed cell death-1 protein (that also helps cancer cells to elude the immune response [166]) and cytotoxic T-lymphocyte-associated protein-4 (an inhibitory receptor from the CD28 immunoglobulin subfamily (reviewed in [167])).